Enhancing the efficacy of nucleoside analogs

增强核苷类似物的功效

• 批准号: 7099557
• 负责人: ARNON LAVIE
• 金额: $ 23.91万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7099557
• 关键词: NOD mouse; SCID mouse; alcohol phosphotransferase; antineoplastics; bone marrow; cell line; clinical research; cytosine arabinoside; deoxycytidine; disease /disorder model; drug delivery systems; drug metabolism; drug screening /evaluation; enzyme activity; enzyme therapy; human genetic material tag; human tissue; immunoconjugates; leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; nonhuman therapy evaluation; nucleoside analog; phosphorylation; prodrugs; synthetic enzyme

DESCRIPTION (provided by applicant): Despite advances in treating hematological malignancies, most patients either do not achieve remission or relapse after an initial therapeutic response. Nucleoside analogues (NAs), including arabinosyl cytosine (ara-C), fludarabine, cladribine, pentostatin, and more recently gemcitabine, troxcitabine and arabinosyl guanine (ara-G), are among the most important therapeutic agents currently used to treat hematological malignancies. Their antitumor activity depends on conversion to active, phosphorylated metabolites by intracellular kinases. Deoxycytidine kinase (dCK) catalyzes the rate-limiting phosphorylation step for the activation of all of these prodrugs. This application seeks (1) to develop a therapeutic system for delivery of dCK to the intracellular compartment to overcome the rate limiting step in NA activation, and (2) to engineer enzymes with improved catalytic activity for this therapeutic system. We will use ara-C as the model chemotherapeutic dCK substrate for these studies and an anti-CD33 antibody as the tumor targeting ligand. CD33 antigen is expressed by myeloid leukemia blasts, but not hematopoietic stem cells or other tissues. We will test the application that this "conjugate therapy" will increase the intracellular form of ara-C (ara-C triphosphate) and enhance its chemotherapeutic effect both in vitro and in vivo. We will manipulate enzyme structure with the goal of increasing both the efficacy and the therapeutic index of combined treatment with nucleoside analogues. Several tumor targeting antibodies are already in clinical use to internalize an attached protein, drug, or radioisotope into tumor cells. The selective delivery of enzymes with increased kinase activity that is proposed here has the potential advantage of reduced toxicity compared with radioisotope and drug systems. The long-term goal of this project is to develop methods to translate this Selective Enhanced Enzyme Delivery System (SEEDS) to applications for multiple types of malignancies.

描述（由申请人提供）：尽管在治疗血液恶性肿瘤方面取得了进展，但大多数患者在初始治疗反应后要么没有达到缓解，要么复发。核苷类似物（NA），包括阿拉伯糖胞嘧啶（ara-C）、氟达拉滨、克拉屈滨、喷司他丁，以及最近的吉西他滨、曲西他滨和阿拉伯糖鸟嘌呤（ara-G），是目前用于治疗血液恶性肿瘤的最重要的治疗药物。它们的抗肿瘤活性取决于细胞内激酶转化为活性磷酸化代谢物。脱氧胞苷激酶 (dCK) 催化限速磷酸化步骤，从而激活所有这些前药。本申请旨在 (1) 开发一种将 dCK 递送至细胞内区室的治疗系统，以克服 NA 激活中的限速步骤，以及 (2) 为该治疗系统设计具有改进催化活性的酶。我们将使用 ara-C 作为这些研究的模型化疗 dCK 底物，并使用抗 CD33 抗体作为肿瘤靶向配体。 CD33 抗原由髓系白血病原始细胞表达，但不由造血干细胞或其他组织表达。我们将测试这种“结合疗法”将增加ara-C（ara-C三磷酸）的细胞内形式并增强其体外和体内化疗效果的应用。我们将操纵酶的结构，以提高核苷类似物联合治疗的功效和治疗指数。几种肿瘤靶向抗体已经在临床使用，将附着的蛋白质、药物或放射性同位素内化到肿瘤细胞中。与放射性同位素和药物系统相比，本文提出的选择性递送具有增加的激酶活性的酶具有降低毒性的潜在优势。该项目的长期目标是开发方法，将这种选择性增强酶递送系统 (SEEDS) 应用于多种类型的恶性肿瘤。